Sarah Okonkwo
325 stories · Page 14 of 14
The Hernia FAQ That Forgets to Mention the Implant
A polished hernia FAQ walks patients through recovery time, return-to-work, and lifestyle. It skips the question with 26,153 pending lawsuits behind it, and the no-mesh option the international guideline still keeps on the table.
Autoimmune & InflammationThe Herbal Steroid That Hits Pharma's Holy-Grail Kidney Target
A Shanghai lab reports a steroid from a Yunnan mountain plant, already sold over the counter to bodybuilders, suppresses the same kidney-fibrosis pathway Big Pharma keeps circling and never quite closes on.
Metabolic & WeightRetatrutide's Triple-Receptor Triumph Came With a One-in-Five Skin-Sensation Signal Nobody Wanted to Linger On
Eli Lilly's investigational retatrutide hit bariatric-surgery-level weight loss at ADA 2026. The highest-dose arm of TRIUMPH-4 also saw 20.9% of patients report abnormal skin sensations, and a small cardiac imbalance turned up in the type-2 trial. Both got far less stage time than the headline numbe
Metabolic & WeightLilly's triple agonist hit 30% weight loss. The glucagon bet is why.
Lilly's triple agonist hit nearly 30% weight loss at 104 weeks at ADA 2026. The glucagon bet is what makes retatrutide different from semaglutide and Mounjaro, and it's what makes the open safety signals different too.
Nutrition & FoodHe Shou Wu's Hair-Loss Pitch Is Better Than I Expected. Its Liver Record Is Worse.
Researchers at Guangdong Pharmaceutical University argue Polygonum multiflorum could become the next pattern-baldness lead. The follicle biology is interesting. The case series of acute liver failure on four continents are not.
InvestigationsA 16-Foot Fire Tornado Burned an Oil Slick With 40% Less Soot. Cleanup Crews Have Been Breathing the Same Old Smoke Since the Exxon Valdez.
A federally funded field trial used a controlled fire whirl to burn up to 95% of a crude oil pool while cutting soot by 40%, raising the question of why the standard in-situ burn, with its measured worker-lung cost, has gone unchallenged for thirty-five years.
InvestigationsCops shoved a doctor at the ADA meeting. The editorial they tore up has its own credibility problem.
Police escorted ADA members out of New Orleans on Friday for passing out an editorial against Trump's NIH overhaul. The shove was bad. The editorial defending the status quo has a credibility problem the press is mostly missing.
Brain & AgingHarvard Just Mapped How a Mouse Smells, and It Quietly Rewrites What Smell Loss Means
Harvard used MERFISH to image roughly 1,100 odorant receptors across the mouse nose at once and found tidy stripes, not chaos. The clinical stakes for smell loss just got harder to wave off.
Metabolic & WeightA gut hormone keeps showing up in the brain's reward circuit, and 600,000 veterans just gave us the biggest hint yet that it matters
A VA cohort of 606,000 diabetic veterans on GLP-1 drugs showed lower risks of new substance use disorders and large drops in overdose and drug-related death versus a peer diabetes drug. The mechanism story is where it gets interesting.
Drugs & FDAThe FDA Approved a Better Penile Implant. For Most Men, ED Is the Heart Warning Them First.
The FDA approved Coloplast's Titan Prime inflatable penile prosthesis on June 3, 2026. For the men whose vasculature is past saving, it is a meaningful device upgrade. For most men with new ED, the more useful conversation is what the small arteries are failing to do years before the coronaries noti
InvestigationsThe Crunchy Mom and the MAHA Mom Were Fighting the Same War. The Pesticide Lobby Won Anyway.
For one strange year, the EWG hiking-boots crowd and the MAHA red-hat moms were fighting the same pesticide war. Then Trump invoked the Defense Production Act on behalf of Bayer, the final MAHA report quietly stopped mentioning glyphosate, and a coalition that was actually winning got stomped by a C
Drugs & FDAAnother Clot Problem at Abiomed: The FDA Flags an Impella Introducer, and the Pattern Keeps Growing
FDA flags Abiomed's 14Fr Low Profile Introducer Kit after a higher than expected complaint rate of clots forming on the device during prolonged Impella CP support. Three serious injuries reported, no deaths. The pattern keeps growing.
Drugs & FDAFDA's New Gene Therapy Shortcut Leans on 'Platform Knowledge.' Six Months Ago, They Revoked Sarepta's After Three Patient Deaths.
FDA's new gene therapy draft guidance invites sponsors to lean on "platform knowledge" to streamline submissions, six months after the agency revoked Sarepta's AAVrh74 platform designation following three patient deaths.